Related Experiment Video
Updated: Jul 16, 2026

Conditional Knockdown of Gene Expression in Cancer Cell Lines to Study the Recruitment of Monocytes/Macrophages to the Tumor Microenvironment
Published on: November 23, 2017
Small interfering RNA-mediated caveolin-1 knockout on plasminogen activator inhibitor-1 expression in
Huiling Yang1, Shuya He, Zhihua Quan
1Institute of Clinic Medicine, the First Affiliated Hospital of Nanhua University, Hengyang, China.
Abstract:
Using human vascular endothelial cells (ECV304) as the target, we studied the effect of caveolin (CAV)-1 in the course of insulin-stimulated expression of plasminogen activator inhibitor (PAI)-1. The appropriate single-stranded oligonucleotides representing the RNAi CAV-1 gene were analyzed by Ambion software. After annealing to generate double-stranded oligonucleotides (ds oligo), it was cloned into the pENTR/U6 entry vector containing RNA polymerase III expression element by T4 DNA ligase. The short hairpin (shRNA) sequences transferred from the pENTR/U6 entry were cloned into the pLenti6/BLOCK-iT-DEST vector with an LR recombination reaction. After identification by sequencing, we successfully constructed the CAV-1 RNAi lentiviral expression system using Gateway technology. Silencing efficiency was assayed by real-time reverse transcription-polymerase chain reaction, immunofluorescence staining and Western blotting. ECV304 cells were cultured in the medium containing different concentrations of insulin (1x10(-9) to 1x10(-7) M) with the CAV-1 gene silenced or not. The expression level and subcellular localization of PAI-1 and CAV-1 were compared using reverse transcription-polymerase chain reaction, immunofluorescence staining and Western blot assay. The results showed that the potent inhibition of CAV-1 expression could reach 85%, and it was specific to the CAV-1-derived shRNA, not the S100A13-derived shRNA. There was no dramatic difference in PAI-1 expression between the RNAi+ and RNAi- ECV304 cells incubated with physiological insulin, but PAI-1 protein did accumulate under the cell membrane. As the concentration of insulin increased, the expression of PAI-1 was up-regulated, whereas the expression of CAV-1 attenuated. Furthermore, PAI-1 clearly augmented after CAV-1 knockdown. These results indicated that hyperinsulinism could promote PAI-1 expression by inhibiting CAV-1, and stabilizing or up-regulating CAV-1 expression in endothelial cells might reduce complications of the great vessels and capillary vessels in diabetes.
Insights
Caveolin-1 (CAV-1) knockdown in endothelial cells increases plasminogen activator inhibitor-1 (PAI-1) expression, suggesting hyperinsulinism promotes PAI-1 by inhibiting CAV-1. Upregulating CAV-1 may prevent diabetic vascular complications.
Area of Science:
- Molecular Biology
- Endothelial Cell Biology
- Cardiovascular Research
Background:
- Caveolin-1 (CAV-1) plays a role in endothelial cell function.
- Insulin signaling impacts vascular health.
- Plasminogen activator inhibitor-1 (PAI-1) is implicated in vascular disease.
Purpose of the Study:
- To investigate the effect of CAV-1 on insulin-stimulated PAI-1 expression in human vascular endothelial cells (ECV304).
- To elucidate the mechanism by which hyperinsulinism influences PAI-1 expression via CAV-1.
- To explore the potential of modulating CAV-1 for preventing diabetic vascular complications.
Main Methods:
- Construction of a CAV-1 RNA interference (RNAi) lentiviral expression system using Gateway technology.
- Validation of CAV-1 silencing efficiency via real-time RT-PCR, immunofluorescence, and Western blotting.
- Culturing ECV304 cells with varying insulin concentrations after CAV-1 gene knockdown and assessing PAI-1 expression and localization.
Main Results:
- CAV-1 knockdown efficiency reached 85% and was specific to CAV-1 shRNA.
- Increased insulin concentrations upregulated PAI-1 expression and downregulated CAV-1 expression.
- CAV-1 knockdown led to augmented PAI-1 expression and its accumulation under the cell membrane.
Conclusions:
- Hyperinsulinism promotes PAI-1 expression by inhibiting CAV-1 in endothelial cells.
- Stabilizing or upregulating CAV-1 expression may offer a therapeutic strategy to mitigate vascular complications in diabetes.
- Targeting CAV-1 could be beneficial for managing diabetic macrovascular and microvascular complications.
More Related Videos
15:55Long-term Silencing of Intersectin-1s in Mouse Lungs by Repeated Delivery of a Specific siRNA via Cationic Liposomes. Evaluation of Knockdown Effects by Electron Microscopy
Published on: June 21, 2013
09:20An Adipocyte Cell Culture Model to Study the Impact of Protein and Micro-RNA Modulation on Adipocyte Function
Published on: May 4, 2021